These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37924363)

  • 41. Efficacy of immune checkpoint inhibitor therapy in patients with
    Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
    Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients.
    Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
    Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
    Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
    Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
    Pu X; Xu C; Wang Q; Wang W; Wu F; Cai X; Song Z; Yu J; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Pang F; Huang J; Wang K; Wu F; Shen T; Zou S; Xu B; Wang L; Zhu Y; Lin X; Cai J; Xu L; Li J; Jiao X; Li K; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Fu J; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Hao Y; Wang Z; Wan B; Lv D; Lan G; Yang S; Shi L; Wang Y; Li B; Zhang Z; Li Z; Li Y; Liu Z; Yang N; Wang H; Huang W; Hong Z; Wang G; Wang J; Fang M; Fang Y; Zhu X; Shen Y; Zhang Y; Ma S; Song Y; Lu Y; Fang W; Li Z; Wu L
    Thorac Cancer; 2023 Nov; 14(31):3166-3177. PubMed ID: 37718634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.
    Wang Y; Xu Y; Wang X; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
    Medicine (Baltimore); 2019 Jan; 98(3):e14120. PubMed ID: 30653139
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
    Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
    J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in the treatment of RET-fusion-positive lung cancer.
    Pall G; Gautschi O
    Lung Cancer; 2021 Jun; 156():136-139. PubMed ID: 33933276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation.
    Chunmao W; Haijie C; Zitong W; Zhi Y
    J Cardiothorac Surg; 2024 Oct; 19(1):554. PubMed ID: 39354540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
    Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
    Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
    Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
    Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Nie T; Syed YY
    Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Selpercatinib in
    Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
    N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
    Song M; Kim SH; Yoon SK
    Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
    Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
    Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive molecular pathology in metastatic thyroid cancer: the role of
    Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
    Hess LM; Han Y; Zhu YE; Bhandari NR; Sireci A
    BMC Cancer; 2021 Jan; 21(1):28. PubMed ID: 33402119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer].
    Courtier B; Pierret T
    Bull Cancer; 2021 Jun; 108(6):562-563. PubMed ID: 34023064
    [No Abstract]   [Full Text] [Related]  

  • 60. Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
    Tsui DCC; Kavanagh BD; Honce JM; Rossi C; Patil T; Camidge DR
    Clin Lung Cancer; 2022 Jan; 23(1):e5-e8. PubMed ID: 34246540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.